AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37364268 — intervention group
Group type: COMPARATOR
Intervention: Control (eating over a period of 10 or more hours per day)
Number of subjects: 90
Study 37364280 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 0
Study 37364280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37364283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor
Number of subjects: 0
Study 37364283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37364590 — intervention group
Group type: EXPERIMENTAL
Intervention: CagriSema (cagrilintide 2·4 mg + semaglutide 2·4 mg)
Number of subjects: 92
Study 37364590 — intervention group
Group type: COMPARATOR
Intervention: semaglutide (2·4 mg)
Number of subjects: 92
Study 37364590 — intervention group
Group type: COMPARATOR
Intervention: cagrilintide (2·4 mg)
Number of subjects: 92
Study 37364600 — intervention group
Group type: EXPERIMENTAL
Intervention: POSE 2.0
Number of subjects: 42
Study 37364600 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone (Control)
Number of subjects: 42
Study 37364669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 174
Study 37364669 — intervention group
Group type: COMPARATOR
Intervention: 12-step facilitation (TSF)
Number of subjects: 174
Study 37364683 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg/d lutein supplementation
Number of subjects: 21
Study 37364683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 37364684 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely-unstable dietary pattern
Number of subjects: 781
Study 37364684 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-delayed dietary pattern
Number of subjects: 781
Study 37364684 — intervention group
Group type: COMPARATOR
Intervention: Timely-stable dietary pattern
Number of subjects: 781
Study 37364684 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-stable dietary pattern
Number of subjects: 781
Study 37364684 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-unstable dietary pattern
Number of subjects: 781
Study 37364685 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP-CT (Hypnosis-enhanced cognitive therapy)
Number of subjects: 53
Study 37364685 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 53
Study 37364710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecnoglutide (subcutaneous injection)
Number of subjects: 0
Study 37364710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37364721 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COVID-19 patients
Number of subjects: 153
Study 37364721 — intervention group
Group type: COMPARATOR
Intervention: Moderate COVID-19 patients
Number of subjects: 153
Study 37364721 — intervention group
Group type: COMPARATOR
Intervention: External cohort of 174 patients with comparable COVID-19 severities
Number of subjects: 153
Study 37364721 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised clustering based on 97 proteins with highest log2 fold changes
Number of subjects: 153
Study 37364721 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotype 3
Number of subjects: 153
Study 37365003 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleepers (<6 hours) without daytime sleepiness or sleep problems
Number of subjects: 740
Study 37365003 — intervention group
Group type: COMPARATOR
Intervention: Short sleepers with daytime sleepiness and sleep problems
Number of subjects: 740
Study 37365046 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) combined with Collaborative Drug Therapy Management (CDTM)
Number of subjects: 322
Study 37365046 — intervention group
Group type: COMPARATOR
Intervention: Control group (BP monitor and instructions for HBPM)
Number of subjects: 322
Study 37365154 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron
Number of subjects: 278
Study 37365154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin saturation
Number of subjects: 278
Study 37365154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin
Number of subjects: 278
Study 37365154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 278
Study 37365210 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based system combining structured symptoms questionnaire and 2-handed spiral drawing
Number of subjects: 77
Study 37365210 — intervention group
Group type: COMPARATOR
Intervention: Symptom questionnaire alone
Number of subjects: 77
Study 37365374 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+EX (calorie restriction plus exercise training)
Number of subjects: 16
Study 37365374 — intervention group
Group type: COMPARATOR
Intervention: Diet-ONLY (calorie restriction alone)
Number of subjects: 16
Study 37365374 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+EX
Number of subjects: 16
Study 37365374 — intervention group
Group type: COMPARATOR
Intervention: Diet-ONLY
Number of subjects: 16
Study 37365439 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Examen
Number of subjects: 71
Study 37365439 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Number of subjects: 71
Study 37365439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 71
Study 37365439 — intervention group
Group type: EXPERIMENTAL
Intervention: Centering Prayer
Number of subjects: 71
Study 37365483 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC3-D3
Number of subjects: 248
Study 37365483 — intervention group
Group type: EXPERIMENTAL
Intervention: AC4-D4
Number of subjects: 248
Study 37365557 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with 3+ doses
Number of subjects: 611
Study 37365557 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation from the source case
Number of subjects: 611
Study 37365557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation of indoor areas
Number of subjects: 611
Study 37365575 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit screen-and-treat (SV-SAT) approach using visual inspection with acetic acid (VIA) and thermal ablation
Number of subjects: 10
Study 37365575 — intervention group
Group type: COMPARATOR
Intervention: Single-visit, screen-and-treat method using cryotherapy
Number of subjects: 10
Study 37365583 — intervention group
Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221 (5 mg/kg, 30-min IV infusion on 4 consecutive days)
Number of subjects: 17
Study 37365583 — intervention group
Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221
Number of subjects: 17
Study 37365596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg daily plus letrozole 2.5 mg daily
Number of subjects: 53
Study 37365597 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 302
Study 37365597 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 302
Study 37365608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 50 mg/dL in DM group
Number of subjects: 1543
Study 37365608 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) < 10 mg/dL in DM group
Number of subjects: 1543
Study 37365608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 50 mg/dL in nonDM group
Number of subjects: 1543
Study 37365608 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) < 30 mg/dL in nonDM group
Number of subjects: 1543
Study 37365608 — intervention group
Group type: EXPERIMENTAL
Intervention: DM with Lp(a) < 30 mg/dL
Number of subjects: 1543
Study 37365608 — intervention group
Group type: EXPERIMENTAL
Intervention: DM with Lp(a) ≥ 30 mg/dL
Number of subjects: 1543
Study 37365614 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 29
Study 37365614 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 29
Study 37365614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical research involvement
Number of subjects: 29
Study 37365618 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily initiated at least 15 days before PCI and maintained until the end of follow-up.
Number of subjects: 42
Study 37365618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SGLT2i).
Number of subjects: 42
Study 37365618 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin group.
Number of subjects: 42
Study 37365618 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 42
Study 37365624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-dominant Romanian deadlift (RDL)
Number of subjects: 32
Study 37365624 — intervention group
Group type: COMPARATOR
Intervention: Knee-dominant Nordic hamstring exercise (NHE)
Number of subjects: 32
Study 37365656 — intervention group
Group type: COMPARATOR
Intervention: Ask about tobacco use; advise to quit; assist with brief counseling (AAA) as standard care
Number of subjects: 1500
Study 37365656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask; advise; connect to phone-based counseling (AAC)
Number of subjects: 1500
Study 37365656 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC + nicotine replacement therapy (NRT)
Number of subjects: 1500
Study 37365665 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (EBD/SEMS)
Number of subjects: 40
Study 37365665 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 40
Study 37365881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) containing drospirenone and ethinylestradiol (EE)
Number of subjects: 858
Study 37365881 — intervention group
Group type: COMPARATOR
Intervention: Placebo COCs
Number of subjects: 858
Study 37365881 — intervention group
Group type: EXPERIMENTAL
Intervention: COCs containing drospirenone and EE
Number of subjects: 858
Study 37365922 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation
Number of subjects: 20
Study 37365922 — intervention group
Group type: COMPARATOR
Intervention: Melasma lesions (no UV exposure)
Number of subjects: 20
Study 37365993 — intervention group
Group type: EXPERIMENTAL
Intervention: Essure
Number of subjects: 47
Study 37366061 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF > 50%
Number of subjects: 33699
Study 37366061 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF around 40% to 50%
Number of subjects: 33699
Study 37366061 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 40%
Number of subjects: 33699
Study 37366061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal LVEF
Number of subjects: 33699
Study 37366061 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF thresholds
Number of subjects: 33699
Study 37366166 — intervention group
Group type: EXPERIMENTAL
Intervention: Step One intervention for traumatized children
Number of subjects: 0
Study 37366166 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing parents’ emotional reactions to a child's trauma
Number of subjects: 0
Study 37366166 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance for parents with lower education
Number of subjects: 0
Study 37366170 — intervention group
Group type: EXPERIMENTAL
Intervention: Birtamimab 24 mg/kg IV + standard of care (SOC)
Number of subjects: 260
Study 37366170 — intervention group
Group type: EXPERIMENTAL
Intervention: Birtamimab 24 mg/kg IV + SOC
Number of subjects: 260
Study 37366170 — intervention group
Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 260
Study 37366170 — intervention group
Group type: EXPERIMENTAL
Intervention: Birtamimab + SOC
Number of subjects: 260
Study 37366260 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational lead exposure
Number of subjects: 0
Study 37366315 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 1 mg
Number of subjects: 338
Study 37366315 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg (combined initial doses of 2 mg and 4 mg)
Number of subjects: 338
Study 37366315 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg (combined initial doses of 2 mg and 4 mg)
Number of subjects: 338
Study 37366315 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg (initial dose of 2 mg)
Number of subjects: 338
Study 37366315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 37366480 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for one year
Number of subjects: 81
Study 37366480 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent group
Number of subjects: 81
Study 37366571 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 144
Study 37366571 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 144
Study 37366590 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-45070, a topical semiselective sodium 1.7 channel (Nav1.7) blocker
Number of subjects: 294
Study 37366614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg by 30-min intravenous infusions every 8 to 24 hours
Number of subjects: 14
Study 37366668 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) therapy with immediate rinsing (Group A)
Number of subjects: 254
Study 37366668 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) therapy with no rinsing for 30 min (Group B)
Number of subjects: 254
Study 37366919 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden of Therapy (BOTh) intervention
Number of subjects: 0
Study 37367448 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality US (including conventional US, strain elastography, and contrast-enhanced US)
Number of subjects: 434
Study 37367448 — intervention group
Group type: COMPARATOR
Intervention: Thyroid Imaging Reporting and Data System (TI-RADS)
Number of subjects: 434
Study 37367978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT): 300 mg clopidogrel on the first day followed by 75 mg daily for 12 days, 100 mg aspirin on the first day followed by 100 mg daily for 12 days, and guideline-based antiplatelet treatment until 90 days.
Number of subjects: 760
Study 37367978 — intervention group
Group type: COMPARATOR
Intervention: Alteplase: intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.
Number of subjects: 760
Study 37368100 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 225 mg twice daily on days 1-2 at 12-h intervals and once on day 3.
Number of subjects: 21
Study 37368103 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 600 mg IV at weeks 0, 4, and 8
Number of subjects: 0
Study 37368103 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 180 or 360 mg SC every 8 or 12 weeks
Number of subjects: 0
Study 37368103 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (UST) 6 mg/kg IV at week 0
Number of subjects: 0
Study 37368103 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (UST) 90 mg SC every 8 or 12 weeks
Number of subjects: 0
Study 37368349 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0
Study 37368401 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based individually tailored self-management support (SELFBACK) adjunct to usual care
Number of subjects: 294
Study 37368401 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nontailored self-management support (e-Help) adjunct to usual care
Number of subjects: 294
Study 37368401 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 294
Study 37368507 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM)
Number of subjects: 1538
Study 37368507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1538
Study 37368512 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 5047
Study 37368512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower insulin sensitivity
Number of subjects: 5047
Study 37368512 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI (in models including both BMI and insulin sensitivity)
Number of subjects: 5047
Study 37368517 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (LED)
Number of subjects: 50
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Local review
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART IRB agreement
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB authorization agreement
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter of support
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwestern sites
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Western sites
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Northeastern sites
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory communication initiated after February 2019
Number of subjects: 85
Study 37368522 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 university affiliation
Number of subjects: 85
Study 37368929 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with oral etoposide chemotherapy
Number of subjects: 0
Study 37368929 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) alone
Number of subjects: 0
Study 37368929 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum biomarkers (CRP, IL-6, IL-10, soluble tumor necrosis factor receptor-2)
Number of subjects: 0
Study 37368929 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifying serum biomarkers (especially CRP)
Number of subjects: 0
Study 37368931 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater paraspinal muscle density (measured in Hounsfield units)
Number of subjects: 708
Study 37368931 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater paraspinal muscle area (cm²/m)
Number of subjects: 708
Study 37368931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower thoracic paraspinal muscle density
Number of subjects: 708
Study 37368992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A Streptococcus rapid antigen detection test
Number of subjects: 256
Study 37369081 — intervention group
Group type: EXPERIMENTAL
Intervention: EV + Pembro
Number of subjects: 149
Study 37369081 — intervention group
Group type: COMPARATOR
Intervention: EV monotherapy
Number of subjects: 149
Study 37369096 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.50-D add multifocal contact lenses
Number of subjects: 3
Study 37369096 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50-D add multifocal contact lenses
Number of subjects: 3
Study 37369096 — intervention group
Group type: COMPARATOR
Intervention: Single-vision contact lenses
Number of subjects: 3
Study 37369099 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-tafasitamab (arm T)
Number of subjects: 66
Study 37369099 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-tafasitamab-lenalidomide (arm T/L)
Number of subjects: 66
Study 37369125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg/day for 1 week
Number of subjects: 32
Study 37369125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 37369125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 32
Study 37369232 — intervention group
Group type: EXPERIMENTAL
Intervention: Orforglipron (12 mg or greater)
Number of subjects: 383
Study 37369232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 37369232 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide
Number of subjects: 383
Study 37369239 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 133
Study 37369239 — intervention group
Group type: COMPARATOR
Intervention: sNIPPV
Number of subjects: 133
Study 37369338 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Sleep Disturbance (ESD) protocol consisting of repeated nights of short and disrupted sleep with intermittent nights of undisturbed sleep, followed by three nights of recovery sleep.
Number of subjects: 24
Study 37369338 — intervention group
Group type: COMPARATOR
Intervention: Control sleep condition with undisturbed sleep opportunity of 8 h/night throughout the protocol.
Number of subjects: 24
Study 37369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastmilk intake
Number of subjects: 27
Study 37369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake from breastmilk
Number of subjects: 27
Study 37369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolizable energy (ME) content of breastmilk
Number of subjects: 27
Study 37369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM) z-score
Number of subjects: 27
Study 37369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (FM) z-score
Number of subjects: 27
Study 37369403 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) testing for malaria
Number of subjects: 1738
Study 37369403 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing by a CHW
Number of subjects: 1738
Study 37369403 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of local CHW
Number of subjects: 1738
Study 37369403 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealthiest households vs least wealthy
Number of subjects: 1738
Study 37369408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation (CI)
Number of subjects: 156
Study 37369409 — intervention group
Group type: EXPERIMENTAL
Intervention: MGPOCUS-guided bronchoscope
Number of subjects: 108
Study 37369409 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscope
Number of subjects: 108
Study 37369412 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (preferred recorded music before, during, and after the operation until day 3 after surgery)
Number of subjects: 189
Study 37369412 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard clinical care)
Number of subjects: 189
Study 37369412 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 189